Needham Reiterates Cogent Biosciences (COGT) Buy Recommendation
Nasdaq Fintel reports that on September 5, 2023, Needham reiterated coverage of Cogent Biosciences (NASDAQ:COGT) with a Buy recommendation.
Analyst Price Forecast Suggests 76.20% Upside
As of August 31, 2023, the average one-year price target for Cogent Biosciences is 22.55. The forecasts range from a low of 18.18 to a high of $28.35. The average price target represents an increase of 76.20% from its latest reported closing price of 12.80.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Cogent Biosciences is 0MM, a decrease of NaN%. The projected annual non-GAAP EPS is -2.12.
What is the Fund Sentiment?
There are 284 funds or institutions reporting positions in Cogent Biosciences. This is an increase of 1 owner(s) or 0.35% in the last quarter. Average portfolio weight of all funds dedicated to COGT is 0.28%, an increase of 16.28%. Total shares owned by institutions increased in the last three months by 18.01% to 94,022K shares. The put/call ratio of COGT is 0.32, indicating a bullish outlook.